Information about Quazepam
Quazepam is an orally available benzodiazepine used to treat insomnia.
Liver safety of Quazepam
As with most benzodiazepines, quazepam therapy has not been associated with serum aminotransferase or alkaline phosphatase elevations, and clinically apparent liver injury from quazepam has not been reported and must be very rare, if it occurs at all.
Mechanism of action of Quazepam
Quazepam (quazepam) is a benzodiazepine used as a sleeping aid in the therapy of insomnia. The antianxiety (anxiolytic) and soporific activity of the benzodiazepines is mediated by their ability to enhance gamma-aminobutyric acid (GABA) mediated inhibition of synaptic transmission through binding to the GABA A receptor.
FDA approval information for Quazepam
Quazepam was approved in the United States in 2007, but is now not commonly used, having been replaced by non-benzodiazepines that bind to the benzodiazepine receptor on the GABA-A receptor complex, which have a shorter duration of action and are better tolerated.
Dosage and administration for Quazepam
Quazepam is available in tablets of 7.5 and 15 mg under the brand name Doral. The recommended initial oral dose for adults is 15 mg at bedtime, which can be decreased to 7.5 mg nightly. Quazepam is recommended only for temporary therapy of insomnia and not as chronic therapy.
Side effects of Quazepam
The most common side effects are dose related and include daytime drowsiness, lethargy, ataxia, dysarthria and dizziness. Tolerance develops to these side effects, but tolerance may also develop to the effects on insomnia.
- Diazepam (Oral)
Drug class for Quazepam